PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
|Articles|October 5, 2015
Dutch Pharmacists Could Offer Pharmacogenetics Services by 2020
October 05, 2015.
Advertisement
Community pharmacists in the Netherlands could offer pharmacogenetics testing, therapeutic support, and advice in as little as 5 years, according to the International Pharmaceutical Federation (FIP).
A plan to implement pharmacogenomics in primary care was launched by the Royal Dutch Pharmacists Association (KNMP) and the Dutch Hospital Pharmacists Association (NVZA) at the World Congress of Pharmacy and Pharmaceutical Sciences last week.
Since 2005, KNMP’s working group on pharmacogenetics has developed recommendations for 80 gene-drug combinations, which are now integrated into the nationwide drug database incorporated into all electronic systems for prescribing and dispensing.
The plan is now in exploration phase and pilot pharmacogenomics laboratory tests by pharmacists and primary care stakeholder analysis are due to start later this year, it is reported.
Advertisement
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
Advertisement
Advertisement
Trending on PharmExec
1
The Impact That the Renewed Focus on Domestic Manufacturing Might Have on the Supply Chain
2
AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
3
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
4
FDA Launches Rare Disease Framework Initiative
5